Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

Terminated

Conditions: Renal Cell Cancer

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Melphalan
Procedure: Stem Cell Transplant

First Posted Date: 2007-01-31

Last Posted Date: 2013-03-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00429026

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: bortezomib
Drug: cyclophosphamide
Drug: prednisone
Drug: vincristine sulfate

First Posted Date: 2007-01-29

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 95

Registration Number: NCT00428142

Locations: 🇨🇦
London Regional Cancer Program, London, Ontario, Canada
🇨🇦
Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
Humber River Regional Hospital, Toronto, Ontario, Canada

and more 16 locations

Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer

Phase 3

Completed

Conditions: Infertility
Menopausal Symptoms
Breast Cancer

First Posted Date: 2007-01-29

Last Posted Date: 2013-08-07

Lead Sponsor: Anglo Celtic Cooperative Oncology Group

Target Recruit Count: 400

Registration Number: NCT00427245

Locations: 🇬🇧
Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood, England, United Kingdom
🇬🇧
Saint Bartholomew's Hospital, London, England, United Kingdom
🇬🇧
Portsmouth Oncology Centre at Saint Mary's Hospital, Portsmouth Hants, England, United Kingdom

and more 63 locations

Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia

Not Applicable

Completed

Conditions: Aplastic Anemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Antithymocyte Globulin

First Posted Date: 2007-01-29

Last Posted Date: 2011-10-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 9

Registration Number: NCT00427336

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Lymphoma
Leukemia

Interventions: Biological: anti-thymocyte globulin
Biological: filgrastim
Biological: graft-versus-tumor induction therapy
Biological: rituximab
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Radiation: total-body irradiation

First Posted Date: 2007-01-23

Last Posted Date: 2017-10-31

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 61

Registration Number: NCT00425802

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Breast Cancer Treated by Neoadjuvant Chemotherapy

Phase 2

Completed

Conditions: Individualized Chemotherapy

Interventions: Drug: Taxotere
Drug: 5-Fluorouracil
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2007-01-23

Last Posted Date: 2014-10-01

Lead Sponsor: Centre Jean Perrin

Target Recruit Count: 264

Registration Number: NCT00425516

Locations: 🇫🇷
Hospital center, Brive La Gaillarde, France
🇫🇷
Centre Jean Perrin, Clermont Ferrand, France
🇫🇷
Edouard Herriot University Hospital, Lyon, France

and more 3 locations

A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.

Phase 3

Terminated

Conditions: Lupus Nephritis

Interventions: Drug: Mycophenolate Mofetil
Drug: Corticosteroids
Drug: Azathioprine
Drug: Cyclophosphamide

First Posted Date: 2007-01-23

Last Posted Date: 2014-09-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 52

Registration Number: NCT00425438

Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis

Phase 1

Terminated

Conditions: Myasthenia Gravis

Interventions: Biological: Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: ATG (rabbit)
Drug: Mesna
Drug: Methylprednisolone
Drug: G-CSF

First Posted Date: 2007-01-19

Last Posted Date: 2018-08-31

Lead Sponsor: Northwestern University

Target Recruit Count: 9

Registration Number: NCT00424489

Locations: 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States

Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery

Phase 2

Completed

Conditions: Breast Cancer
Cognitive/Functional Effects
Depression
Malnutrition
Psychosocial Effects of Cancer and Its Treatment

Interventions: Drug: AC regimen
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Procedure: adjuvant therapy
Procedure: cognitive assessment
Procedure: management of therapy complications
Procedure: psychosocial assessment and care
Procedure: quality-of-life assessment

First Posted Date: 2007-01-18

Last Posted Date: 2013-09-04

Lead Sponsor: UNICANCER

Target Recruit Count: 40

Registration Number: NCT00424203

Locations: 🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷
Centre Regional Rene Gauducheau, Nantes-Saint Herblain, France
🇫🇷
Centre Henri Becquerel, Rouen, France

and more 14 locations

Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer

Phase 2

Completed

Conditions: Cancer

Interventions: Drug: CYCLOPHOSPHAMIDE
Drug: MEGESTROL

First Posted Date: 2007-01-11

Last Posted Date: 2012-07-23

Lead Sponsor: Centre Oscar Lambret

Target Recruit Count: 88

Registration Number: NCT00420563

Locations: 🇫🇷
Centre Hospitalier Regional - Dermatology, Lille, France
🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷
Hopital Saint Vincent, Lille, France

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy